Fiche centre
Leeds General Infirmary
Leeds — United Kingdom
Essais liés8clinical trials
VilleLeedslocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05701358
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Right Greater Splanchnic Nerve (GSN) ablation | Insuffisance cardiaque | Non applicable | NCT07403058 | R-HFrEF — Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction | RECRUITING |
| Physiology-guided NCL PCI | Maladie coronarienne | Non applicable | NCT05701358 | COMPLETE-2 — Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease | ACTIVE_NOT_RECRUITING |
| Vagus Nerve Stimulation (VNS) Therapy | SEP | Phase 4 | NCT01118455 | Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures | TERMINATED |
| ENTR-601-44 | Myopathies | Phase 2 | NCT07682129 | Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) | NOT_YET_RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 3 | NCT06298552 | ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| ENTR-601-45 | Myopathies | Phase 1/2 | NCT07038824 | ELEVATE-45 — A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | RECRUITING |
| ENTR-601-44 | Myopathies | Phase 1/2 | NCT07037862 | ELEVATE-44 — A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |